Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Toons & Teasers
Industry
 Directory
 Toons & Teasers
Quick Links
 Directory
 Job Search
 Toons & Teasers
 Advertising
 
Jobs
 

EquipNet Auction: Sell Your Surplus Equipment on Our Global Marketplace Now!

Our Newest Cartoon Illustrates: "The Biology of Valentines"


Washington Life Science Industry Directory

https://www.cdc.gov/flu/prevent/index.html

Banner Advertising

Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and delayed by COVID-19, to be launched in 2023 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved directory upon the launch of the new site. We apologize for the inconvenience.

Covance Drug Development


Covance Drug Development
9911 Willows Rd NE, Suite 175
Redmond, WA 98052
Covance Drug Development
 
Phone: (425) 979-5000
Fax: (425) 979-5001
Year Established:  1997
Employees: 319
Ticker: LH
Exchange: NYSE
Main Contact: John Ratliff, CEO
 
Other Contacts:  Jonathan Zung, Group President, Clinical Development
Herman E. Scholtz, MD, VP & GM, Early Clinical Services
Jonathan Koch, Group President, R&D Laboratories
Chris Gegelys, General Counsel
John Gransee, CFO
Honggang Bi, GM, China
Steven Anderson, CSO
Dimitris K. Agrafiotis, PhD, FRSC, Chief Data Officer
 
Company Description
Covance (formerly Merck/Rosetta) is one of the world's largest and most comprehensive drug development services companies, with annual revenues greater than $2 billion, global operations in more than 30 countries, and more than 11,000 employees worldwide.

Covance offers development services such as safety assessment, clinical pharmacology, consulting, to late-stage development services that include clinical trial management, central laboratory testing, central diagnostics, and commercializationt.

On Feb. 19, 2015, LabCorp® announced the completion of its acquisition of Covance. At closing, the purchase consideration was valued at $107.19 per Covance share, consisting of $75.76 in cash and 0.2686 LabCorp shares for each Covance share, or an equity value of $6.2 billion and an enterprise value of $5.7 billion.



Main Industry Directory

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 1997 - 2023 Info.Resource, Inc. All rights reserved.
Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

WashingtonLifeScience.com is owned and published by Info.Resource, Inc.